SecBot SecBot

SEPN drug pipeline

Septerna, Inc. · 3 rated drugs
$42.60
+1.8% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketIf Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).

SEP-479 Updated Nov 9

What to watch

The next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.

Bull case
  • SEP-479 is a potential first-in-class oral small-molecule PTH1R agonist for hypoparathyroidism, offering a convenient oral alternative to the current injectable standard of care (YORVIPATH), which could capture significant market share.
  • Preclinical data presented at ENDO 2026 showed promising results, and the Phase 1 trial in up to 150 healthy volunteers was initiated in April 2026 with data expected by late 2026 or early 2027.
  • Analyst consensus is Strong Buy (mean recommendation 1.1 on a 1-5 scale) with a mean price target of $56.78 (14% upside from the current ~$50), and multiple firms (HC Wainwright, Stifel, Wells Fargo) have raised targets citing SEP-479 progress.
Bear case
  • SEP-479 is still in Phase 1 with no human efficacy data yet; the transition from promising preclinical results to clinical proof-of-concept is the highest-risk point for any new drug.
  • The hypoparathyroidism market already has an approved injectable therapy (YORVIPATH/palopegteriparatide from Ascendis Pharma), and Entera Bio is developing an oral PTH peptide (EB612), creating a competitive landscape.
  • Elevated short-sale volume (z-score of 1.95 vs the stock's own history) and insider selling under 10b5-1 plans suggest some near-term caution among informed market participants.
● neutral
Impact
PhasePhase 1 completed; Phase 2 planned
Time to marketIf Phase 2 trials begin in late 2026 or early 2027, topline data would likely be 12-18 months out. Assuming positive Phase 2 and Phase 3 results, potential FDA approval would be several years away, likely 2029 or later.

SEP-631 Updated Nov 9

What to watch

Watch for Septerna's Q3 2026 earnings call and press release (filed Nov 9, 2026) for updates on SEP-631 Phase 2 trial initiation timeline in chronic spontaneous urticaria. The next major catalyst is Phase 2 topline data, likely 12-18 months out. SEP-479 (PTH1R agonist for hypoparathyroidism) Phase 1 data is another pipeline catalyst to monitor.

Bull case
  • Phase 1 data was strongly positive: SEP-631 demonstrated robust, dose-dependent inhibition of mast cell activity with complete skin wheal suppression at doses as low as 10 mg once-daily, and was well-tolerated with an adverse event profile comparable to placebo.
  • As an oral small molecule, SEP-631 could offer a more convenient alternative to injectable biologics like Xolair and Dupixent, potentially capturing a large share of the CSU market where 89% of patients report uncontrolled symptoms on antihistamines.
  • Analyst consensus is strongly bullish: 15 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $56.78 (14.2% upside from $49.72). HC Wainwright (75% accuracy on SEPN) and Truist Securities (67%) rate it a Buy.
Bear case
  • The CSU treatment landscape is increasingly crowded: Xolair (omalizumab), Dupixent (dupilumab), and Novartis' oral BTK inhibitor remibrutinib (approved in the UK) are already on the market, while Celldex's barzolvolimab has shown positive Phase 2 data. SEP-631 would need to differentiate on efficacy, safety, or convenience as an oral drug.
  • SEP-631 is still early-stage (Phase 1 completed, Phase 2 not yet initiated). Clinical-stage biotech stocks carry high risk of trial failure, and many promising Phase 1 assets fail to replicate results in larger Phase 2/3 studies.
  • Insider selling has been notable: the President/COO sold shares in October 2026, and major holders RA Capital Management and Third Rock Ventures sold large blocks in August 2026. The 90-day bull/bear checklist shows a net bearish signal with elevated short-sale volume (z-score 1.95).
● neutral
Impact
PhasePreclinical (Development Candidate Selected)
Time to marketSEP-204 is in preclinical development with a Phase 1 trial planned to begin in Q1 2027. Assuming successful clinical development, potential approval would likely be several years away, likely in the 2030s if at all.

SEP-204 Updated Nov 6

What to watch

The next catalyst for SEP-204 is the planned Phase 1 trial initiation in healthy volunteers in Q1 2027, roughly 4-5 months away. A successful start would validate the transition from preclinical to clinical-stage for this program, but the stock's bigger near-term driver is likely the Q3 2026 earnings report scheduled for November 25, 2026, and any updates on the more advanced SEP-631 (MRGPRX2 NAM) program.

Bull case
  • SEP-204 is a potential first-in-class oral small molecule TSHR negative allosteric modulator that could offer a disease-modifying treatment for Graves' disease and thyroid eye disease, addressing a significant unmet need.
  • Preclinical data presented at the 2026 American Thyroid Association meeting showed potent and selective TSHR inhibition, restoration of thyroid hormone T4 levels toward normal, and reduced thyroid enlargement and orbital proptosis in animal models.
  • Septerna has a strong cash position of $516.5 million (as of June 30, 2026), funding operations at least into 2029, which eliminates near-term dilution risk for advancing SEP-204 and the broader pipeline.
Bear case
  • SEP-204 is still preclinical with no human data; the drug could fail to show safety or tolerability in the Phase 1 trial planned for Q1 2027.
  • The TSHR antagonist space is getting crowded: Crinetics has CRN12755 (preclinical TSHR antagonist) and Merida Biosciences (acquired by Lilly) has MER-511 in Phase 1, a different but competitive approach targeting the same receptor.
  • As a development candidate selected only on November 4, 2026, SEP-204 is years away from any potential approval, and preclinical efficacy does not guarantee clinical success.